Takeda Pharmaceutical
TAK
18.37
+0.27
+1.49%
Takeda Pharmaceutical
US · TAK
#400 by market cap
Listed 1970
18.37
+0.27
+1.49%
Live - 5344 symbols - heartbeat 58s ago
· 2026-10-08 05:53
Pre-market
18.40
+0.16%
After-hours
18.37
0.00%
Overnight
18.34
-0.16%
- Market cap
- 58.68B
- P/E (TTM)i
- -55.67
- P/Bi
- 1.23
- EPSi
- -0.31
- Div yieldi
- 3.26%
- 52W posi
- 88%
Reader sentiment
Are you bullish or bearish on TAK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.48, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -1.66% YoY
Margins
- Gross margin
- 65.12%
- Operating margin
- 10.31%
- Net margin
- -3.38%
Key ratios & quality
- Enterprise valuei
- 4.30T
- Altman Z-Scorei
- 0.48
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.10T | 3.29T | 3.20T | 3.57T | 4.03T | 4.26T | 4.58T | 4.51T |
| Gross profit | 1.45T | 2.20T | 2.20T | 2.46T | 2.78T | 2.84T | 3.00T | 2.93T |
| Selling & admin expenses | 717.60B | 964.74B | 875.66B | 886.36B | 997.31B | 1.05T | 1.10T | 1.08T |
| Research & development | 368.30B | 492.38B | 455.83B | 526.09B | 633.33B | 729.92B | 730.23B | 675.92B |
| Operating profit | 192.28B | 286.74B | 417.55B | 546.04B | 587.81B | 309.90B | 466.37B | 464.45B |
| Pretax profit | 127.61B | -60.75B | 366.24B | 302.57B | 375.09B | 52.79B | 175.08B | -142.36B |
| Tax | -7.47B | -105.04B | -9.94B | 72.41B | 58.05B | -91.41B | 66.94B | 9.77B |
| Net profit | 135.08B | 44.29B | 376.17B | 230.17B | 317.04B | 144.20B | 108.14B | -152.13B |
| Basic EPS | 70 | 14 | 120 | 74 | 102 | 46 | 34 | -48 |
| Diluted EPS | 69.91 | 14.13 | 119.48 | 72.94 | 100.97 | 45.58 | 33.62 | -48.38 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.05T | 1.11T | 1.11T | 1.19T | 1.09T | 1.22T |
| Gross profit | 671.32B | 722.01B | 732.74B | 790.55B | 688.84B | 813.22B |
| Selling & admin expenses | 295.87B | 255.89B | 253.55B | 282.78B | 292.00B | 286.51B |
| Research & development | 216.01B | 143.89B | 161.48B | 175.23B | 195.32B | 167.40B |
| Operating profit | 48.85B | 184.57B | 69.00B | 168.82B | 42.07B | 201.42B |
| Pretax profit | -107.30B | 150.63B | 28.17B | 133.86B | -455.02B | 162.72B |
| Tax | -4.20B | 26.35B | 39.90B | 30.13B | -86.62B | 49.46B |
| Net profit | -103.10B | 124.28B | -11.73B | 103.73B | -368.41B | 113.26B |
| Basic EPS | -33 | 40 | -4 | 33 | -117 | 36 |
| Diluted EPS | -32.68 | 39.12 | -3.92 | 32.34 | -117.03 | 35.27 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.99T | 2.47T | 2.71T | 2.59T | 2.40T | 2.56T | 2.52T | 3.09T |
| Cash & ST investments | 725.37B | 653.44B | 1.00T | 875.00B | 553.70B | 472.89B | 405.59B | 636.94B |
| Inventory | 919.67B | 759.60B | 753.88B | 853.17B | 986.46B | 1.21T | 1.22T | 1.40T |
| Total assets | 13.79T | 12.82T | 12.91T | 13.18T | 13.96T | 15.11T | 14.25T | 15.51T |
| Total current liabilities | 2.55T | 2.18T | 1.77T | 2.15T | 2.48T | 2.31T | 2.51T | 2.83T |
| Short-term debt | 984.95B | 586.82B | 22.15B | 203.99B | 339.60B | 367.25B | 548.94B | 512.16B |
| Long-term debt | 4.77T | 4.51T | 4.61T | 4.14T | 4.04T | 4.48T | 3.97T | 4.37T |
| Total liabilities | 8,606,782,000,000.00 | 8,093,608,000,000.00 | 7,735,116,000,000.00 | 7,494,495,000,000.00 | 7,603,079,000,000.00 | 7,834,787,000,000.00 | 7,312,365,000,000.00 | 8,080,857,000,000.00 |
| Total equity | 5.19T | 4.73T | 5.18T | 5.68T | 6.35T | 7.27T | 6.94T | 7.43T |
| Retained earnings | 1.60T | 1.37T | 1.51T | 1.48T | 1.54T | 1.39T | 1.19T | 712.38B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.52T | 2.51T | 2.92T | 3.12T | 3.09T | 3.15T |
| Cash & ST investments | 405.59B | 419.18B | 739.68B | 761.94B | 636.94B | 527.58B |
| Inventory | 1.22T | 1.24T | 1.30T | 1.41T | 1.40T | 1.45T |
| Total assets | 14.25T | 14.00T | 14.47T | 15.41T | 15.51T | 15.66T |
| Total current liabilities | 2.51T | 2.17T | 2.14T | 2.61T | 2.83T | 2.76T |
| Short-term debt | 548.94B | 371.14B | 293.86B | 583.15B | 512.16B | 519.97B |
| Long-term debt | 3.97T | 4.13T | 4.35T | 4.27T | 4.37T | 4.42T |
| Total liabilities | 7,312,365,000,000.00 | 7,138,357,000,000.00 | 7,338,611,000,000.00 | 7,764,684,000,000.00 | 8,080,857,000,000.00 | 8,104,395,000,000.00 |
| Total equity | 6.94T | 6.87T | 7.13T | 7.64T | 7.43T | 7.56T |
| Retained earnings | 1.19T | 1.16T | 1.15T | 1.10T | 712.38B | 667.01B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 328.48B | 669.75B | 1.01T | 1.12T | 977.16B | 716.34B | 1.06T | 1.04T |
| Depreciation & amortization | 247.69B | 583.65B | 559.67B | 583.15B | 664.40B | 728.00B | 761.40B | 721.13B |
| Free cash flow | 194.37B | 452.04B | 774.46B | 937.07B | 343.47B | 235.61B | 677.56B | 626.77B |
| Dividends paid | -142.95B | -282.58B | -283.36B | -283.67B | -279.42B | -287.19B | -302.50B | -311.90B |
| Stock buybacks / issuance | -1.17B | -3.74B | -2.14B | -77.53B | -26.93B | -2.33B | -51.86B | -51.60B |
| Ending cash balance | 702.09B | 637.61B | 966.22B | 849.70B | 533.53B | 457.80B | 385.11B | 595.05B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 222.16B | 215.40M | 593.44B | 373.25B | 74.53B | 127.60M |
| Depreciation & amortization | 189.77B | 181.64B | 184.98B | 190.64B | 163.87B | -- |
| Free cash flow | 129.44B | 215.40M | 465.54B | 150.88B | 10.14B | 127.60M |
| Dividends paid | -9.74B | -145.30B | -8.79B | -149.03B | -8.79B | -- |
| Stock buybacks / issuance | -49.98B | -51.60B | 0 | 0 | 0 | -- |
| Ending cash balance | 385.11B | 350.00M | 681.49B | 654.94B | 595.05B | 461.00M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 3.05 | 0.90 | 7.60 | 4.24 | 5.27 | 2.11 | 1.52 | -2.12 |
| ROA %i | 1.21 | 0.33 | 2.92 | 1.76 | 2.34 | 0.99 | 0.74 | -1.02 |
| ROIC %i | 1.99 | 1.35 | 4.74 | 3.22 | 3.96 | 1.93 | 1.53 | -0.62 |
| 5-year avg ROE %i | 3.39 | 4.83 | 5.57 | 5.22 | 4.35 | 4.02 | 4.15 | 2.20 |
| EBIT margin %i | 6.82 | 2.68 | 15.54 | 11.91 | 12.22 | 4.04 | 6.82 | 0.13 |
| FCF / sales %i | 9.27 | 13.73 | 24.22 | 26.26 | 8.53 | 5.53 | 14.79 | 13.91 |
| Current ratioi | 1.17 | 1.13 | 1.53 | 1.21 | 0.97 | 1.11 | 1.01 | 1.09 |
| Quick ratioi | 0.58 | 0.66 | 1.02 | 0.75 | 0.50 | 0.51 | 0.45 | 0.53 |
| Debt / assetsi | 41.70 | 39.73 | 35.90 | 32.97 | 31.40 | 32.06 | 31.69 | 31.47 |
| LT debt / equityi | 91.97 | 95.41 | 89.18 | 72.87 | 63.62 | 61.55 | 57.19 | 58.82 |
| Interest coveragei | 2.97 | 0.59 | 3.80 | 3.47 | 4.21 | 1.44 | 2.28 | 0.04 |
| Revenue CAGR (3Y) %i | 5.08 | 23.86 | 21.78 | 19.39 | 6.96 | 10.06 | 8.68 | 3.81 |
| Net income CAGR (3Y) %i | 19.03 | -27.26 | 26.24 | 19.39 | 92.79 | -27.37 | -22.30 | -- |
| FCF CAGR (3Y) %i | -- | 44.66 | 45.86 | 68.93 | -8.75 | -32.74 | -10.25 | 22.20 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 1.52 | 1.87 | 0.47 | 1.50 | -2.12 | -2.27 |
| ROA %i | 0.74 | 0.91 | 0.23 | 0.74 | -1.02 | -1.10 |
| ROIC %i | 1.53 | 1.83 | 0.85 | 1.44 | -0.62 | -0.68 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 6.82 | 8.35 | 6.73 | 11.13 | 0.13 | -0.55 |
| FCF / sales %i | 14.79 | 17.88 | 20.88 | 16.71 | 13.91 | 13.57 |
| Current ratioi | 1.01 | 1.16 | 1.36 | 1.19 | 1.09 | 1.14 |
| Quick ratioi | 0.45 | 0.51 | 0.67 | 0.58 | 0.53 | 0.54 |
| Debt / assetsi | 31.69 | 32.17 | 32.10 | 31.50 | 31.47 | 31.54 |
| LT debt / equityi | 57.19 | 60.23 | 61.02 | 55.87 | 58.82 | 58.48 |
| Interest coveragei | 2.28 | 2.02 | 1.49 | 1.70 | 0.04 | -0.24 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Gastroenterology (GI) is the largest reported line at 31.65% of revenue, across 7 reported segments.
- No single line clears half of revenue; Plasma Derived Therapies (PDT) is next at 23.27%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Gastroenterology (GI)31.65%
Plasma Derived Therapies (PDT)23.27%
Rare Diseases16.89%
Oncology13.57%
Neuroscience9.31%
Other4.16%
Vaccines1.15%
Quote time 2026-10-08 05:53:46 · For reference only, not investment advice and not tailored to your situation.